1-4 of 4
John McKay
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Use of Fidanacogene Elaparvovec, a Gene Therapy Vector, to Deliver a Stable, Fully Functional Human Factor IX Transgene for the Treatment of Hemophilia B: A Combined Analysis of Safety

Ben Samelson-Jones, Laurent Frenzel, Kaan Kavakli, Adam Cuker, Jerome M. Teitel, Pengling Sun, Lisa J Wilcox, Francesca Biondo, Benjamin Hutter, John McKay, Delphine Agathon, Frank Plonski
Journal: Blood
Blood (2024) 144 (Supplement 1): 3577.
https://doi.org/10.1182/blood-2024-193453
Published: 2024
Journal Articles

Characterizing a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec from the Phase 3 Benegene-2 Study Who Returned to Factor IX Prophylaxis

Laurent Frenzel, Kaan Kavakli, Robert Klamroth, Shyh-Shin Chiou, Amy D. Shapiro, Pengling Sun, Joanne Fuiman, John McKay, Annie F. Fang, Francesca Biondo, Frank Plonski, Jeremy Rupon
Journal: Blood
Blood (2023) 142 (Supplement 1): 2257.
https://doi.org/10.1182/blood-2023-181223
Published: 2023
Journal Articles

Venetoclax and Cytarabine in AML Transformed from Myelofibrosis

John McKay, DO, Matthew Gayhart, MD, Taha Al-Juhaishi, MD, Victor Yazbeck, MD, Edward B. Perkins, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5140.
https://doi.org/10.1182/blood-2019-129429
Published: 2019
Journal Articles

Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

John McKay, DO, Taha Al-Juhaishi, MD, Lai Guanhua, MD PhD, Maciej Kmieciak, PhD, Roy Sabo, PhD, Ariel Sindel, DO, Victor Yazbeck, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5482.
https://doi.org/10.1182/blood-2019-126335
Published: 2019